Company: ICUI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0000883984-25-000035
Chunk: 53

Company: ICU MEDICAL INC/DE
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 1
Chunk 53
---
)Currency translation155 14 169 Accrued balance, March 31, 2025$7,712 $1,913 $9,625 Charges incurred4,289 3,934 8,223 Payments(3,930)(2,538)(6,468)Currency translation287 95 382 Accrued balance, June 30, 2025$8,358 $3,404 $11,762 Charges incurred2,901 3,267 6,168 Payments(3,409)(3,389)(6,798)Currency translation41 (26)15 Accrued balance, September 30, 2025$7,891 $3,256 $11,147 __________________________(1)  Relates to prior year accrued restructuring charges for estimated severances costs that were reclassed to other accounts during the three months ended March 31, 2025.Strategic Transaction and Integration Expenses    We incurred and expensed $6.9 million and $24.9 million in strategic transaction and integration expenses during the three and nine months ended September 30, 2025, respectively, as compared to $13.2 million and $33.5 million in strategic transaction and integration expenses during the three and nine months ended September 30, 2024, respectively, which are included in restructuring, strategic transaction and integration expenses in our condensed consolidated statements of operations. The strategic transaction and integration expenses during the three and nine months ended September 30, 2025 and 2024 were primarily related to ongoing consulting expenses and employee costs incurred to integrate our Smiths Medical business acquired in 2022. The nine months ended September 30, 2025 also included transaction costs related to the sale of a 60% ownership in our IV Solutions business in the second quarter of 2025.

11

ICU MEDICAL, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Continued)

Note 4:  Assets Held For Sale and Disposal of Business

Assets Held For SaleOn November 12, 2024, we entered into a purchase agreement (the "Agreement") with Otsuka Pharmaceutical Factory America, Inc., a Delaware corporation ("OPF") to divest a controlling interest in our IV Solutions business. As of December 31, 2024, we concluded the initial criteria for